Pharmacokinetic Evaluation of Efanesoctocog Alfa Versus Other Extended Half-Life Recombinant Factor VIII Products in Severe Haemophilia A Patients

The primary objective of this study is to conduct a **pharmacokinetic** comparison of efanesoctocog alfa with other extended half-life recombinant factor VIII (EHL-rFVIII) products in participants with severe **haemophilia A**. This comparison is clinically relevant as it aims to evaluate the efficacy and safety of efanesoctocog alfa, potentially offering improved therapeutic options for individuals with this bleeding disorder.

The clinical trial focuses on participants diagnosed with **Haemophilia A**. The study population consists exclusively of male subjects, as female subjects are not included. Participants fall within the age range category of 3, which typically corresponds to adults aged 18 to 64 years. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria, including lifestyle considerations such as diet, physical activity, or habits, have not been specified. Key inclusion or exclusion criteria are not detailed in the available data.

The clinical trial is designed to evaluate the **pharmacokinetics** of efanesoctocog alfa compared to other extended half-life recombinant factor VIII (EHL-rFVIII) products in participants with severe **haemophilia A**. This study is a Phase 2, randomized, double-blind, controlled trial. The estimated recruitment start date is April 2, 2024, with an anticipated end date of September 16, 2024. The trial will involve a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Participants will then be randomized to receive either the investigational product or a comparator, with follow-up visits scheduled to monitor safety, efficacy, and pharmacokinetic parameters. The end-of-study visit will conclude the trial, during which final assessments will be conducted to gather comprehensive data on the investigational product's performance.

Participants are expected to be involved in the study for the duration of the trial, from the initial screening through to the end-of-study visit. Conditions that may lead to early termination from the study include adverse events, withdrawal of consent, or non-compliance with the study protocol. The trial's design ensures that data collected will contribute to understanding the pharmacokinetic profile of efanesoctocog alfa, potentially informing future therapeutic strategies for managing severe haemophilia A.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **active substances**, their origin, and the **product authorization status** are not included. The trial documentation does not provide the sponsor product code or any additional relevant information about the drug administration process.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on April 2, 2024, with an estimated completion date of September 16, 2024. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The focus will be on evaluating the therapeutic impact of the investigational product over the course of the study period. The trial will adhere to rigorous standards to ensure the reliability and validity of the efficacy outcomes.